Article Text

PDF

A5.27 Ro52 Expression is a Prognostic Factor for Survival in B Cell Lymphoma
  1. Susanna Brauner1,
  2. Wei Zhou1,
  3. Carin Backlin2,
  4. Tina M Green3,4,
  5. Ken He Young5,
  6. Björn Löfström6,
  7. Ingrid Lundberg1,
  8. Lars Møller Pedersen5,
  9. Michael Boe Møller4,5,
  10. Christer Sundström7,
  11. Gunilla Enblad7,
  12. Eva Baecklund3,
  13. Marie Wahren-Herlenius1
  1. 1Rheumatology Research Unit, Department of Medicine, Karolinska Institutet, Stockholm, Sweden
  2. 2Unit of Rheumatology, Department of Medical Sciences, Uppsala University, Uppsala, Sweden
  3. 3Institute of Clinical Research, University of Southern Denmark
  4. 4Odense University Hospital, Odense, Denmark
  5. 5MD Anderson Cancer Center, The University of Texas, Houston, USA
  6. 6Rheumatology Clinic, Malar hospital, Eskilstuna, Sweden
  7. 7Department of Genetics and Pathology, Rudbeck laboratory, Uppsala University, Uppsala, Sweden

Abstract

Background and Objectives The risk for lymphoma is increased in many rheumatic conditions. Diffuse Large B-cell Lymphoma (DLBCL) is a common, yet heterogeneous lymphoma subtype and good prognostic biomarkers are warranted. We have previously shown that the rheumatic autoantigen Ro52 is expressed predominantly in leukocytes and that over expression affects lymphocyte proliferation. Further, the Ro52 (Trim21) gene maps to a tumour suppressor locus. We therefore hypothesised that Ro52 expression might be used as a prognostic marker for lymphoma.

Materials and Methods Proliferation of in vitro stimulated lymphocytes was determined by thymidine incorporation and cell cycle analysis and compared to Ro52 mRNA levels. Three cohorts of patients with DLBCL were investigated for Ro52 expression by immunohistochemistry using monoclonal Ro52 antibodies. The first cohort consisted of patients with rheumatic disease treated with cytostatic drugs only (n = 43). The two others were non-rheumatic patients treated with anthracycline-based (CHOP) therapy alone (n = 74), and with the addition of Rituximab (n = 196).

Results A robust inverse correlation between Ro52 expression levels and cellular proliferation was observed (r2 = 0.50, p < 0.0001). Confirming this biological phenomenon, low expression of Ro52 in lymphoma tissue was significantly correlated to overall survival (p < 0.0001), as well as progression-free survival (p < 0.0001) in patients with DLBCL treated with CHOP therapy alone. This was further confirmed in the Rituximab-CHOP treated cohort, with a significantly lower overall survival (p < 0.0001) and progression-free survival (p = 0.0005). The association was independent of Ann Arbor classification and DLBCL subtype, emphasising that Ro52 expression is a parameter of added value in lymphoma investigations to understand the patient prognosis.

Conclusions Our data demonstrate that low Ro52 expression is associated with more aggressive lymphomas. Further, our data functionally link low Ro52 expression with increased cellular proliferation. Ro52 may thus constitute a novel biologically relevant biomarker predicting patient survival in lymphoma.

Statistics from Altmetric.com

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.